Daiichi Sankyo Looks At Consolidating Stake In Zenotech; Minority Shareholders, Founder Cry Hoarse
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Daiichi Sankyo, the majority equity holder in India's largest drug company Ranbaxy, has encountered a hurdle in its proposal to make an open offer for 20 percent shares in Zenotech Labs. Shareholders of Zenotech Labs have pleaded that the open offer price fixed by Daiichi Sankyo is far less than what Ranbaxy paid to acquire 46 percent of its equity a year ago